Analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a research note issued on Sunday. The brokerage set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Stock Down 4.2 %
NASDAQ IRIX opened at $1.81 on Friday. The firm has a market capitalization of $29.42 million, a P/E ratio of -2.70 and a beta of 0.78. The company has a 50-day moving average price of $1.96 and a 200-day moving average price of $2.36. IRIDEX has a 52 week low of $1.63 and a 52 week high of $3.65.
IRIDEX (NASDAQ:IRIX – Get Free Report) last released its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). IRIDEX had a negative net margin of 21.84% and a negative return on equity of 134.37%. The company had revenue of $12.63 million for the quarter, compared to analysts’ expectations of $12.80 million. During the same quarter last year, the firm posted ($0.17) earnings per share. As a group, equities research analysts anticipate that IRIDEX will post -0.52 EPS for the current year.
Institutional Trading of IRIDEX
IRIDEX Company Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Articles
- Five stocks we like better than IRIDEX
- How to Buy Cheap Stocks Step by Step
- The Average 401k Balance by Age Explained
- ESG Stocks, What Investors Should Know
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- The 3 Best Blue-Chip Stocks to Buy Now
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.